{
    "clinical_study": {
        "@rank": "158008", 
        "acronym": "ASPIRE", 
        "arm_group": {
            "arm_group_label": "Cytovir-ADV", 
            "arm_group_type": "Experimental", 
            "description": "Adenovirus-specific T-cells"
        }, 
        "brief_summary": {
            "textblock": "Human Adenovirus-specific T-cells can persist and augment impaired adenovirus immune\n      response post allogeneic haematopoietic stem cell transplant, and reduce the requirement for\n      antiviral therapy without toxicity or increasing the occurrence of Graft Versus Host\n      Disease. This is a Phase I/IIa open-label safety study, assessing the effects of\n      administering adenovirus-specific T-cells (Cytovir ADV) to paediatric patients post\n      haematopoietic stem cell transplant."
        }, 
        "brief_title": "Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "ADV Infection Post Allo-HSCT", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients:\n\n          1. Age 16 years or younger\n\n          2. Scheduled to undergo an allogeneic HSCT with an unrelated donor, mismatched unrelated\n             donor, mismatched family donor or haplo identical donor\n\n          3. The subject (or legally acceptable representative) must give informed consent (and\n             assent for subjects \u2265 12 years). All subjects will have a parent or guardian provide\n             informed consent and the subject will provide witnessed verbal assent\n\n          4. Negative serology for HIV 1 + 2, HepB, HepC, Syphilis, hCG.\n\n        Donors\n\n          1. Meets requirements of Directive 2004/23/EC as amended and the UK statutory\n             instruments pursuant therein\n\n          2. Negative serology for HIV 1 + 2, HepB, HepC, Syphilis, hCG\n\n          3. Passed medical assessment for stem cell donation\n\n          4. HdADV seropositive\n\n          5. Signed informed consent\n\n          6. Age 16 years or older\n\n        Exclusion Criteria:\n\n        Patients\n\n          1. Pregnant or lactating females\n\n          2. Co-existing medical problems that would place the patient at significant risk of\n             death due to GVHD or its sequelae\n\n          3. Human Immunodeficiency Virus (HIV) infection\n\n        Donors\n\n          1. Pregnant or lactating females\n\n          2. (assessed prior to apheresis) Platelets < 50x109/L"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "16 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822093", 
            "org_study_id": "CM-2011-02"
        }, 
        "intervention": {
            "arm_group_label": "Cytovir-ADV", 
            "description": "A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results > 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at \u2265 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.\nThis is a feasibility/pilot study and has no control group", 
            "intervention_name": "Cytovir-ADV", 
            "intervention_type": "Biological", 
            "other_name": "Adenovirus-specific T-cells"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 27, 2013", 
        "link": {
            "url": "http://www.controlled-trials.com/ISRCTN22322271/ASPIRE"
        }, 
        "location": {
            "contact": {
                "email": "w.qasim@ucl.ac.uk", 
                "last_name": "Dr Waseem Qasim"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Great Ormond Street Hospital"
            }, 
            "investigator": {
                "last_name": "Waseem Qasim", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation", 
        "overall_official": {
            "affiliation": "Institute of Child Health, London", 
            "last_name": "Waseem Qasim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with new onset GVHD", 
                "safety_issue": "Yes", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "number of subjects developing NCI Grade 3-4 adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "180 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822093"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of reported Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs) and Suspected Expected Serious Adverse Reactions (SESARs)", 
                "safety_issue": "Yes", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Number of detectable HAdV-specific T-cells in vivo at each time point", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Requirement for second infusion of HAdV-specific T-cells", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Number of treatment days with antiviral drugs", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Number of treatment days with other anti-infective drugs", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }, 
            {
                "measure": "Number of in-hospital days during 6 month post-infusion period", 
                "safety_issue": "No", 
                "time_frame": "180 days"
            }
        ], 
        "source": "Cell Medica Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "United Kingdon: Technology Strategy Board", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Cell Medica Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}